First Successful Below-The-Knee Angioslide Embolic Capture Performed in U.S.

The new 3x100 mm, low-profile Proteus device successfully captured and removed embolic material in below-the-knee interventions

 

July 13, 2012

July 13, 2012 — Angioslide Ltd., a provider of embolic capture angioplasty solutions, today announced the successful deployment of a 3x100 mm Proteus device for treating peripheral artery disease (PAD) in below-the-knee (BTK) vasculature at Community Hospital in Munster, Ind. Accommodating a 0.014 inch guide-wire, the new device allows physician to perform a percutaneous transluminal angioplasty (PTA) revascularization in BTK vessels while capturing and removing embolic particles.

Angioslide’s proprietary technology combines the functionality of a balloon angioplasty device with the addition of capture and removal of particles released during intervention.  Capture of embolic material is enabled by the inward folding of the balloon through a dedicated handle, which creates a suction effect that pulls embolic material into the cavity.  When retrieved through the sheath, Proteus removes the captured material from the body.

The Proteus device addresses an unmet need for an easy-to-use, efficient and cost-effective embolic removal solution for the peripheral vascular disease market. It is the first device of its kind to receive U.S. Food and Drug Administration (FDA) clearance for use in lower limbs (the femoral, iliac, ilio-femoral, popliteal, tibial, peroneal, and profunda arteries). The device has also received European CE mark approval for lower limb use and is being marketed in selected regions in Europe. Angioslide headquarters are located in Caesarea, Israel, and Denver Colo.

For more information: www.angioslide.com

 

 

The content of this field is kept private and will not be shown publicly.
Type the characters you see in this picture. (verify using audio)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated. Not case sensitive.